详情页 - 河北医科大学第四医院机构库

当前位置：首页 > 详情页

Combination Chemotherapy of Lung Cancer - Co-Delivery of Docetaxel Prodrug and Cisplatin Using Aptamer-Decorated Lipid-Polymer Hybrid Nanoparticles

8| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Baoding 1 Cent Hosp, Dept Thorac Surg, Baoding, Hebei, Peoples R China [2]Hebei Med Univ, Dept Thorac Surg, Hosp 2, Shijiazhuang, Hebei, Peoples R China [3]Hebei Med Univ, Tumor Hosp Hebei Prov, Dept Thorac Surg, Hosp 4, Shijiazhuang, Hebei, Peoples R China

出处：

DOI：

ISSN：

关键词： lung cancer combination therapy docetaxel prodrug cisplatin aptamer-decorated lipid-polymer hybrid nanoparticles

摘要：

Purpose: Lung cancer is the leading cause of cancer mortality worldwide. Drug resistance is the major barrier for the treatment of non-small cell lung cancer (NSCLC). The aim of this research is to develop an aptamer-decorated hybrid nanoparticle for the co-delivery of docetaxel prodrug (DTXp) and cisplatin (DDP) and to treat lung cancer. Materials and Methods: Aptamer-conjugated lipid-polymer ligands and redox-sensitive docetaxel prodrug were synthesized. DTXp and DDP were loaded into the lipid-polymer hybrid nanoparticles (LPHNs). The targeted efficiency of aptamer-decorated, DTXp and DDP co-encapsulated LPHNs (APT-DTXp/DDP-LPHNs) was determined by performing a cell uptake assay by flow cytometry-based analysis. In vivo biodistribution and anticancer efficiency of APT-DTXp/DDP-LPHNs were evaluated on NSCLC-bearing mice xenograft. Results: APT-DTXp/DDP-LPHNs had a particle size of 213.5 +/- 5.3 nm, with a zeta potential of 15.9 +/- 1.9 mV. APT-DTXp/DDP-LPHNs exhibited a significantly enhanced cytotoxicity (drug concentration causing 50% inhibition was 0.71 +/- 0.09 mu g/mL), synergy antitumor effect (combination index was 0.62), and profound tumor inhibition ability (tumor inhibition ratio of 81.4%) compared with the non-aptamer-decorated LPHNs and single drug-loaded LPHNs. Conclusion: Since the synergistic effect of the drugs was found in this system, it would have great potential to inhibit lung tumor cells and in vivo tumor growth.

语种：

被引次数：

WOS：

PubmedID：

中科院分区：

出版当年[2020]版：

大类 | 3 区医学

小类 | 3 区药物化学 3 区药学

最新[2025]版：

大类 | 2 区医学

小类 | 2 区药物化学 2 区药学

JCR分区：

出版当年[2020]版：

Q2 CHEMISTRY, MEDICINAL Q2 PHARMACOLOGY & PHARMACY

最新[2023]版：

Q1 CHEMISTRY, MEDICINAL Q1 PHARMACOLOGY & PHARMACY

影响因子： 4.7 最新[2023版] 4.8 最新五年平均 4.162 出版当年[2020版] 4.278 出版当年五年平均 3.216 出版前一年[2019版] 4.319 出版后一年[2021版]

第一作者：

第一作者机构： [1]Baoding 1 Cent Hosp, Dept Thorac Surg, Baoding, Hebei, Peoples R China

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Pursuing for the better lung cancer therapy effect: Comparison of two different kinds of hyaluronic acid and nitroimidazole co-decorated nanomedicines [2]Synergistic combination therapy of lung cancer: Cetuximab functionalized nanostructured lipid carriers for the co-delivery of paclitaxel and 5-Demethylnobiletin [3]Long-term survival after combination therapy with atezolizumab in a patient with small-cell lung cancer: a case report [4]晚期非小细胞肺癌化疗联合免疫治疗进展 [5]Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer [6]Lung cancer chemotherapy using nanoparticles: Enhanced target ability of redox-responsive and pH-sensitive cisplatin prodrug and paclitaxel. [7]BIOMARKER ANALYSIS OF A RANDOMIZED, CONTROLLED, MULTICENTER CLINICAL TRIAL COMPARING PEMETREXED/CISPLATIN AND GMCITABINE/CISPLATIN AS FIRST-LINE TREATMENT FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER [8]放射治疗在晚期食管鳞癌的地位及研究进展 [9]Nanoparticle-based combination therapy enhances fulvestrant efficacy and overcomes tumor resistance in ER-positive breast cancer [10]Combination of metformin and gefitinib as first-line therapy for nondiabetic advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: A multicenter, randomized, double-blind, placebo-controlled phase II trial.